With the advent of successful vaccination against COVID-19, much of the world has moved forward to a safer coexistence with the virus. But for very young children, vaccines have only been available through emergency use authorization and lacked longer-term analysis of their safety, effectiveness and optimum dosing. New findings from Seattle Children’s Research Institute’s Center for Clinical and Translational Research reveal the vaccine’s safety and efficacy in children ages 6 months to 4 years.
Pediatric hospitals and providers across the nation, including Seattle Children’s lead study investigator Dr. Janet Englund, published findings in the New England Journal of Medicine showing a 3-microgram dose of the Pfizer COVID-19 vaccine was safe and effective in young children when given as three doses.
